How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

582 results for

Progestin Androgenic Activity

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

21. IUD with progestogen

(copper or levonorgestrel) that is released. Exposure to a foreign body causes a sterile inflammatory reaction in the intrauterine environment that is toxic to sperm and ova and impairs implantation. 28,29 The production of cytotoxic peptides and activation of enzymes lead to inhibition of sperm motility, reduced sperm capacite journal and survival, and increased phagocytosis of sperm. 30,31 … The progestin in the LNg IUC enhances the contraceptive action of the device by thickening cervical mucus (...) and the specific action of the medication (copper or levonorgestrel) that is released. Exposure to a foreign body causes a sterile inflammatory reaction in the intrauterine environment that is toxic to sperm and ova and impairs implantation.28,29 The production of cytotoxic peptides and activation of enzymes lead to inhibition of sperm motility, reduced sperm capacite journal and survival, and increased phagocytosis of sperm.30,31… The progestin in the LNg IUC enhances the contraceptive action of the device

2012 Wikipedia

22. Body fat mass is associated with ratio of steroid metabolites reflecting 17,20-lyase activity in prepubertal girls. Full Text available with Trip Pro

morning blood samples were drawn at a university hospital to measure serum steroid profiles using gas chromatography-mass spectrometry, and steroidogenic enzyme activities were assessed from the ratios of steroid metabolites.We evaluated serum steroid profiles and estimated steroidogenic enzyme activities and their association with anthropometric indices and body composition.Prepubertal obese girls demonstrated significantly higher progestin, androgens (dehydroepiandrosterone [DHEA], androstenedione (...) with pregnenolone, DHEA, A-dione, T, androsterone, and ratio of (DHEA + A-dione)/17-hydroxypregnenolone in prepubertal girls only. Prepubertal girls with increased body fat mass had significantly higher serum DHEA and ratio of (DHEA + A-dione)/17-hydroxypregnenolone than controls.Increased androgen production in prepubertal obese girls could be at least partly due to increased body fat mass and 17,20-lyase activity.

2016 Journal of Clinical Endocrinology and Metabolism

23. Effects and mechanisms of progestogens and androgens in ictal activity. (Abstract)

Effects and mechanisms of progestogens and androgens in ictal activity. Steroid hormones, such as progestogens and androgens, influence seizures. Progestogens and androgens exert organizational and/or activational effects that may mitigate vulnerability to, and/or expression of, some seizure disorders. Progestogens, such as progesterone (P(4)) and its 5alpha-reduced metabolite, 5alpha-pregnan-3alpha-ol-20-one (3alpha,5alpha-THP), which vary across the reproductive cycle and lifespan, may (...) protect against seizures through actions at intracellular progestin receptors (PRs) and membrane receptors, such as gamma-aminobutyric acid (GABA)(A) receptors. Similarly, androgens, such as testosterone (T), which also vary across the reproductive cycle and the lifespan, can have antiseizure effects. Some of these effects of T may be due to aromatization to estrogen and/or 5alpha-reduction to dihydrotestosterone (DHT), and its subsequent conversion through 3alpha-hydroxysteroid dehydrogenase

2010 Epilepsia

24. A Study With an Open-Label Active Control to Evaluate the Potential of Nestorone® to Delay Cardiac Repolarization in Healthy Female Volunteers

of oral glucocorticoid replacement therapy in 12 months prior to Screening. Has experienced undiagnosed genital bleeding, excluding inter-menstrual spotting, within 6 months of Screening; Has undergone a gynecological examination, which results in clinically significant abnormalities, at Screening; Has had treatment with oral, topical or vaginal steroid hormones (e.g., estrogens, progestogens, androgens [including dehydroepiandrosterone], corticosteroids) within 8 weeks prior to Screening (...) A Study With an Open-Label Active Control to Evaluate the Potential of Nestorone® to Delay Cardiac Repolarization in Healthy Female Volunteers A Study With an Open-Label Active Control to Evaluate the Potential of Nestorone® to Delay Cardiac Repolarization in Healthy Female Volunteers - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save

2014 Clinical Trials

25. Progestin-induced virilisation

., for in protocols or for prevention of in pregnant women with a history of at least one spontaneous preterm birth) are: progesterone, hydroxyprogesterone caproate, dydrogesterone, and allylestrenol. Doses of 19-nortestosterones required for virilization are 10 to 20 mg/day, far in excess of those associated with inadvertent exposure during pregnancy. Genital ambiguity due to progestin exposure in pregnancy is thus mostly a topic of historical concern. History [ ] Androgens [ ] The first drugs reported to cause (...) and might prevent , but oral of progesterone is low and injections of progesterone can be painful, so orally active progestins were tried beginning with , followed by other progestins as they became available: noretynodrel (Enovid) and norethisterone (Norlutin) in 1957, medroxyprogesterone acetate (Provera) in 1959, norethisterone acetate (Norlutate) in 1961, and dydrogesterone (Duphaston) in 1962. The first case reports of fetal masculinization of external genitalia of female infants born to mothers

2012 Wikipedia

26. Lybridos in Pre- and Postmenopausal Women With Hypoactive Sexual Desire Disorder Due to Maladaptive Activation of Sexual Inhibitory Systems

and/or diastolic blood pressure ≥ 90 mmHg Systolic blood pressure ≤ 90 mmHg and/or diastolic blood pressure ≤ 50 mmHg. Gynecological and Obstetric Conditions Use of any contraceptive containing antiandrogens (e.g. Cyproteron acetate) or(anti)androgenic progestogens (drospirenone, dienogest, chlormadinone acetate and norgestrel) Use of any contraceptive or hormone replacement therapy (HRT) containing more than 50 μg/day of estrogen Positive test result for Chlamydia or gonorrhea Pregnancy or intention to become (...) Lybridos in Pre- and Postmenopausal Women With Hypoactive Sexual Desire Disorder Due to Maladaptive Activation of Sexual Inhibitory Systems Lybridos in Pre- and Postmenopausal Women With Hypoactive Sexual Desire Disorder Due to Maladaptive Activation of Sexual Inhibitory Systems - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study

2012 Clinical Trials

27. Effects of Androgen Blockade on Sensitivity of the GnRH Pulse Generator to Suppression by Estradiol and Progesterone

Effects of Androgen Blockade on Sensitivity of the GnRH Pulse Generator to Suppression by Estradiol and Progesterone Effects of Androgen Blockade on Sensitivity of the GnRH Pulse Generator to Suppression by Estradiol and Progesterone - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number (...) of saved studies (100). Please remove one or more studies before adding more. Effects of Androgen Blockade on Sensitivity of the GnRH Pulse Generator to Suppression by Estradiol and Progesterone The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT01428193 Recruitment Status : Terminated (Haven't enrolled

2011 Clinical Trials

28. European Society of Endocrinology Clinical Practice Guideline: Endocrine work-up in obesity

? LH in women ? oestrogens/androgens Insulin resistance 25-OH vitamin D ? Trapping in adipose tissue, ? sun exposure ? 25OH vitamin D binding protein ? liver synthesis PTH N or ? Secondary due to vitamin D deficiency Insulin ? Insulin resistance Renin ? ? Sympathetic tone Aldosterone ? ? Adipokines, renin- angiotensin, leptin GLP-1 ? ? FFA, microbiota Leptin ? Increased adipose mass, Leptin resistance Ghrelin ? Lack of ghrelin decrease after meals 11-HSD, 11ß-hydroxysteroid dehydrogenase; ACTH (...) globulin; TSH, thyroid-stimulating hormone. Downloaded from Bioscientifica.com at 02/19/2020 06:38:23AM via free accessEuropean Journal of Endocrinology 182:1 G6 Clinical Practice Guideline R Pasquali and others ESE Guidelines on Endocrine work-up in obesity https://eje.bioscientifica.com Table 2 Examples of endocrine diseases/disturbances causing or contributing to obesity. Condition Prevalence in obesity When to think about it First diagnostic procedure Androgen deficiency (men) Common Severe obesity

2020 European Society of Endocrinology

29. Ovarian Stimulation for IVF/ICSI

at baseline 35 KEY QUESTION: What is the prognostic value of hormonal assessment at baseline? 35 2.1 Baseline oestradiol 35 2.2 Progesterone 35 References 36 3. Pre-treatment therapies 37 KEY QUESTION: DOES HORMONE PRE-TREATMENT IMPROVE EFFICACY AND SAFETY OF OVARIAN STIMULATION? 37 3.1 OESTROGEN PRE-TREATMENT 37 3.2 PROGESTOGEN PRE-TREATMENT 38 3.3 COMBINED ORAL CONTRACEPTIVE PILL PRE-TREATMENT 38 3.4 GNRH ANTAGONIST PRE-TREATMENT 39 REFERENCES 40 PART B: LH SUPPRESSION AND OVARIAN STIMULATION 42 [4] 4 (...) cycle 51 REFERENCES 52 5. LH suppression regimes 54 KEY QUESTION: Which LH suppression protocol is preferable? 54 5.1 GnRH agonist protocols 54 5.2 GnRH antagonist protocol 55 5.3 Progestin 57 References 57 6. Types of gonadotropins 60 KEY QUESTION: Is the type of stimulation drug associated with efficacy and safety? 60 6.1 RECOMBINANT FSH (RFSH) 60 6.2 HIGHLY PURIFIED FSH (HP-FSH) VS HUMAN MENOPAUSAL GONADOTROPIN (HMG) 63 6.3 HUMAN MENOPAUSAL GONADOTROPIN (HMG) VS RECOMBINANT FSH + RECOMBINANT LH

2019 European Society of Human Reproduction and Embryology

30. Drug-Induced Liver Injury

characteristicsofthedrugareimportant,particularlylipophilic- ity and drug biotransformation. This exposes the liver to reac- tive metabolites which can covalently bind to proteins, induce oxidative stress, activate signal transduction pathways (e.g. mitogen-activated protein (MAP) kinases) and result in orga- nelle stress (e.g. mitochondrial or endoplasmic reticulum (ER) stress), interfere with bile acid transport and either lead to lethal consequences (necrosis or apoptosis) or induce adaptive responses which dampen (...) illnesses, and chronic alcoholic abuse modulate the threshold toxic dose by in?uencing CYP2E1 (the main enzyme which con- verts acetaminophen to a reactive metabolite) or glutathione status (main detoxi?cation factor). If glutathione is severely depleted, particularly in mitochondria, the toxic metabolite covalently binds to mitochondrial proteins and induces increased reactive oxygen species (ROS) production. The latter activates the MAPK pathway leading to sustained activation of c-Jun N-terminal

2019 European Association for the Study of the Liver

31. Gynecologic Management of Adolescents and Young Women With Seizure Disorders

have increased seizure activity with puberty and menarche due to the neuroactive properties of endogenous steroid hormones . Endogenous estrogens have proconvulsant and epileptogenic properties, although the mechanism by which estradiol increases neuronal excitability is not well understood . Natural serum progesterone has been found to reduce seizures, and a decrease in progesterone or progesterone–estradiol ratio during specific times of an ovulatory menstrual cycle is associated with increased (...) seizure activity . Compared with patients without epilepsy, patients with epilepsy are more likely to experience anovulatory cycles, irregular menstrual bleeding, and amenorrhea ; both the epileptic discharges and the antiepileptic drugs have been implicated as potential causes of these menstrual abnormalities . Antiepileptic drugs themselves may affect reproductive health as well as contraceptive choice and efficacy; some antiepileptic drugs are teratogens . Prospective studies have found evidence

2020 American College of Obstetricians and Gynecologists

32. AIM Cancer Treatment Pathways

’ clinical scenario NHL: Follicular And Marginal Zone Lymphoma Pathways ? Clarified the use of generic antibiotic therapy for H. Pylori Prostate Cancer (Adenocarcinoma) Pathways ? Existing regimens including abiraterone and enzalutamide clarified to note “the use of androgen-signaling–targeted inhibitor (e.g. abiraterone or enzalutamide) should be limited to one line of therapy” Note: Pathways are independent of specific health plan medical policy coverage criteria. Health plan medical policy/clinical

2020 AIM Specialty Health

33. Oestrogen deficiency symptoms in postmenopausal women: conjugated oestrogens and bazedoxifene acetate

significantly reduced the average daily number of moderate and severe hot flushes from baseline compared with placebo. However no active control group was included in this study. This makes it difficult to determine how conjugated oestrogens and bazedoxifene compare to established treatments for vasomotor symptoms such as conjugated oestrogens and progestogen. The SMART 3 trial investigated the effect of conjugated oestrogens and bazedoxifene 0.45 mg/20 mg on vulvar or vaginal atrophy. First- line (...) smokers (more than 15 cigarettes per day) were excluded. Transvaginal ultrasound was completed at screening. Women in whom endometrial thickness could not be measured, or those with endometrial thickness of greater than 4 mm, focal endometrial abnormality, or complex or simple ovarian cysts (depending on the size) were excluded. Participants could not have used oral oestrogen, progestin, androgen or selective oestrogen receptor modulator-containing drugs, transdermal hormone products, intrauterine

2017 National Institute for Health and Clinical Excellence - Advice

34. Risk Factors for Endometrial Cancer - A review of the evidence

). Two recent cohort studies reported on the association of tibolone, a synthetic steroid MHT with estrogenic, progestagenic and androgenic properties, and risk of endometrial cancer. 95, 97 Mørch et al. (2016) 97 showed that tibolone is associated with an increased risk of endometrial cancer in ever users compared with never users (RR 3.56, 95%CI 2.94–4.32). Løkkegaard and Mørch (2018) 95 extended the analysis of the Danish Sex Hormone Register Study to show that risk of endometrial cancer (...) Intrauterine device (IUD) contraception 36 3.4.4 Menopausal hormone therapy/Hormone replacement therapy 38 3.5 Lifestyle factors 42 3.5.1 Alcohol consumption 42 3.5.2 Body fatness 44 3.5.3 Coffee and tea 47 3.5.4 Diet ?acrylamide 51 3.5.5 Diet ?fat 52 3.5.6 Diet ?glycaemic load 53 3.5.7 Environmental tobacco smoke 55 Endometrial cancer risk factors: A review of the evidence iii 3.5.8 Physical activity 56 3.5.9 Sedentary behaviour 58 3.5.10 Tobacco smoking 60 3.5.11 Weight loss 62 3.6 Medical factors 64

2019 Cancer Australia

35. Estradiol

indication that conjugated equine estrogens are more thrombogenic and most likely induce some (...) hypertensive responses; estradiol might also be superior to conjugated equine estrogens (CEE) in terms of global cardiovascular health. The most valid evidence presently suggests that CEE-only treatment does not increase the risk of breast cancer and even may reduce it. But its combination with a synthetic progestogen (mainly medroxyprogesterone acetate) is a critical issue since it seems to be primarily (...) demographic characteristics were associated with unscheduled bleeding, absent scheduled 2016 6. 17β- Estradiol and natural progesterone for menopausal hormone therapy: REPLENISH phase 3 study design of a combination capsule and evidence review. Several formulations combining estrogens and progestins for hormone therapy (HT) have been approved worldwide for the treatment of menopausal symptoms, yet recent data indicate a decline in their use and an increase in compounded bioidentical HT. Up to now

2018 Trip Latest and Greatest

36. ESC/ESH Management of Arterial Hypertension Full Text available with Trip Pro

day) ONTARGET Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial PAC Plasma aldosterone concentration PAD Peripheral artery disease PATHS Prevention and Treatment of Hypertension Study PRA Plasma renin activity PRC Plasma renin concentration PROGRESS Perindopril protection against recurrent stroke study PWV Pulse wave velocity RAS Renin–angiotensin system RCT Randomized controlled trial RWT Relative wall thickness SBP Systolic blood pressure SCOPE Study on Cognition

2018 European Society of Cardiology

37. International evidence-based guideline for the assessment and management of polycystic ovary syndrome (PCOS)

Council (NHMRC) through the funded Centre for Research Excellence in Polycystic Ovary Syndrome (CREPCOS) (APP1078444) and the members of this Centre who led and co-ordinated this international guideline effort 2 Our partner organisations which co-funded the guideline: ? American Society for Reproductive Medicine (ASRM) ? European Society of Human Reproduction and Embryology (ESHRE) 3 Our collaborating and engaged societies and consumer groups: ? Androgen Excess and Polycystic Ovary Syndrome Society (...) Exercise interventions 79 3.5 Obesity and weight assessment 82 CONTENTS International evidence-based guideline for the assessment and management of polycystic ovary syndrome 2018 3 Chapter Four Pharmacological treatment for non-fertility indications 84 4.1 Pharmacological treatment principles in PCOS 85 4.2 Combined Oral Contraceptive Pills and & combined oral contraceptive pills in 4.3 combination with other agents 86 4.4 Metformin 91 4.5 Anti-obesity pharmacological agents 95 4.6 Anti-androgen

2018 European Society of Human Reproduction and Embryology

38. Menopause

endometrial hyperplasia (thickening of the womb) which may occur with oestrogen-only therapy (Grady et al., 1995). Progestogens are given in one of three ways: • cyclical – usually resulting in a monthly bleed • tricyclical – usually resulting in bleeds every three months • continuous – ‘no-bleed’ therapy (some irregular bleeding initially) for post- menopausal women. HRT can also be given as a gonadomimetic, a synthetic hormone which comprises oestrogenic, progestogenic and androgenic properties. Figure (...) and progestogen contraception or high-dose progestogen, as the diagnostic accuracy of the FSH blood test may be confounded by these treatments: • women aged over 45 years with atypical symptoms • women between 40–45 years with menopausal symptoms, including a change in their menstrual cycle • women younger than 40 years in whom premature menopause is suspected. Contraception at peri-menopause Women should be informed that effective contraception should be used in the peri-menopause, although

2018 Royal College of Nursing

39. Nutrition in Chronic Liver Disease

or uptake of nutrition that leads to altered body composition (decreased fat free mass) and body cell mass, leading to diminished physical and mental function and impaired clinical outcome from disease. In the present CPGs, we have used “malnutrition” as a synonym of “undernutrition” Synonym of malnutrition (see above) The active, progressive loss of muscle mass due to an underlying disease, ultimately leading to muscle atrophy. Most inflammatory diseases, malnutrition and increased catabolism induce (...) liver disease. J Hepatol (2018), https://doi.org/10.1016/j.jhep.2018.06.024the presence and severity of malnutrition, 17–19 in order to actively manage this complication. Nutrition screening tools Twosimplecriteriastratifypatientsathighriskofmalnutrition: beingunderweight,de?nedasabodymassindex(BMI)(kg.body weight [BW]/[height in meters] 2 ) 30kg/m 2 ) always consider the confounding effect of ?uid retention and estimate dry BW, even though the accuracy is low. (Grade II-2, B2) Include

2018 European Association for the Study of the Liver

40. Screening and Management of the Hyperandrogenic Adolescent

active) testosterone. Although most data about the treatment of hyperandrogenism are on OCPs, similar effects have been shown with the patch and vaginal ring formulations (17, 18). Among the formulations, OCPs that contain third- generation progestins, such as desogestrel, gestodene, and norgestimate, have less androgenic activity when compared withsecond-generationprogestins(levonorgestrel).Drospir- enone, a progestin derived from spironolactone, has anti (...) ,whichconvertstestosteronetothe highly potent dihydrotestosterone. Varying expression of enzyme activity within the pilosebaceous unit leads to a lack of clear correlation between serum androgens and the presence or severity of acne and hirsutism. There also may be ethnic and familial variability (5). Polycystic ovary syndrome is the most common cause of persistent hyperandrogenism beyond early puberty in adolescent girls and women and is estimated to affect 6– 15% of reproductive-aged women (6). In this syndrome

2019 American College of Obstetricians and Gynecologists

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>